Machine learning framework for prediction of drug‐induced liver injury in patients on antitubercular therapy: Multicentric study

Aims Antitubercular drug‐induced liver injury (AT‐DILI) is the leading cause of drug‐induced liver injury in India, yet integrated risk stratification models remain inadequately defined. This study aimed to identify baseline determinants of AT‐DILI and to develop machine learning models for its risk prediction at two Indian tertiary centres. Methods In this multicentre prospective cohort study conducted from August 2021 to January 2025, 695 treatment‐naïve adults with newly diagnosed tuberculosis were followed during first‐line therapy. AT‐DILI was diagnosed using modified American Thoracic Society (ATS) criteria. Baseline demographic, clinical, biochemical and nutritional variables informed predictive modelling. Nine machine learning algorithms were evaluated using stratified shuffle split cross‐validation (10 iterations; 66:34 train–test split) and assessed by the area under the receiver operating characteristic curve (AUC‐ROC), area under the precision‐recall curve (AUPRC), F1‐score, precision, recall and calibration. Results AT‐DILI incidence was 79/695 patients (11.4%), with geographic variation (Jodhpur: 8.5% [37/435]; Manipal: 16.2% [42/260]). State‐based differences reached significance (OR:1.67; 95% CI:1.02–2.74). The baseline urea‐to‐albumin ratio was significantly elevated in patients who developed AT‐DILI (6.13 vs . 5.02; p = .015), whereas conventional liver function tests lacked predictive value. Most cases (84.2%) manifested by Week 2 (65.8% at Week 2; 18.4% earlier), marked by elevated alanine aminotransferase (ALT) (115 vs . 19 IU L −1 ; p < .001), aspartate aminotransferase (AST) (124 vs . 24 IU L −1 ; p < .001), and bilirubin (0.67 vs . 0.52 mg dL −1 ; p = .002). Gradient boosting showed the highest discrimination (AUC 0.97; precision 0.95; F1‐score 0.75; recall 0.62), followed by random forest (AUC 0.92). Conclusions Baseline demographic, clinical and biochemical profiling enhances AT‐DILI risk stratification. Gradient boosting demonstrated the highest performance (AUC 0.97), followed by random forest (AUC 0.92).

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-09-25
DOI
https://doi.org/10.1002/bcp.70838
Primary Topic
Drug-Induced Hepatotoxicity and Protection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Machine learning framework for prediction of drug‐induced liver injury in patients on antitubercular therapy: Multicentric study

Kavitha Saravu, Manoj Khokhar, Hemant Borana, Mithu Banerjee et al.
British Journal of Clinical Pharmacology
Drug-Induced Hepatotoxicity and Protection
article

Machine learning framework for prediction of drug‐induced liver injury in patients on antitubercular therapy: Multicentric study

Kavitha Saravu, Manoj Khokhar, Hemant Borana, Mithu Banerjee, Sarika Kombade, Sojit Tomo, Namya Sethi, Amal Mohandas, Mitali Mathur, Naveen Dutt, Muralidhar Varma, Mahadev Rao, Praveen Sharma, Snigdha Singh, Yashi Batra, Levin Thomas, Nishant Chauhan
article en

Abstract

Aims Antitubercular drug‐induced liver injury (AT‐DILI) is the leading cause of drug‐induced liver injury in India, yet integrated risk stratification models remain inadequately defined. This study aimed to identify baseline determinants of AT‐DILI and to develop machine learning models for its risk prediction at two Indian tertiary centres. Methods In this multicentre prospective cohort study conducted from August 2021 to January 2025, 695 treatment‐naïve adults with newly diagnosed tuberculosis were followed during first‐line therapy. AT‐DILI was diagnosed using modified American Thoracic Society (ATS) criteria. Baseline demographic, clinical, biochemical and nutritional variables informed predictive modelling. Nine machine learning algorithms were evaluated using stratified shuffle split cross‐validation (10 iterations; 66:34 train–test split) and assessed by the area under the receiver operating characteristic curve (AUC‐ROC), area under the precision‐recall curve (AUPRC), F1‐score, precision, recall and calibration. Results AT‐DILI incidence was 79/695 patients (11.4%), with geographic variation (Jodhpur: 8.5% [37/435]; Manipal: 16.2% [42/260]). State‐based differences reached significance (OR:1.67; 95% CI:1.02–2.74). The baseline urea‐to‐albumin ratio was significantly elevated in patients who developed AT‐DILI (6.13 vs . 5.02; p = .015), whereas conventional liver function tests lacked predictive value. Most cases (84.2%) manifested by Week 2 (65.8% at Week 2; 18.4% earlier), marked by elevated alanine aminotransferase (ALT) (115 vs . 19 IU L −1 ; p < .001), aspartate aminotransferase (AST) (124 vs . 24 IU L −1 ; p < .001), and bilirubin (0.67 vs . 0.52 mg dL −1 ; p = .002). Gradient boosting showed the highest discrimination (AUC 0.97; precision 0.95; F1‐score 0.75; recall 0.62), followed by random forest (AUC 0.92). Conclusions Baseline demographic, clinical and biochemical profiling enhances AT‐DILI risk stratification. Gradient boosting demonstrated the highest performance (AUC 0.97), followed by random forest (AUC 0.92).

British Journal of Clinical Pharmacology
Manipal Academy of Higher Education (IN), All India Institute of Medical Sciences Jodhpur (IN), Sarojini Naidu Medical College (IN)
Openalex Percentile: Top 9%
Drug-Induced Hepatotoxicity and Protection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.